We are live on ! Find out more

Pacific Biosciences

PACB

Market cap $420M

1.35 USD

+0.05

3.85%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

1.34

-0.01

0.74%

1 day

3.85%

5 days

0.75%

1 month

17.39%

3 months

2.27%

6 months

-0.74%

Year to date

-26.63%

1 year

12.5%

5 years

-95.21%

10 years

-83.73%

About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Employees: 485

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 17.4%

Neutral 52.2%

Negative 30.4%

Zacks Investment Research

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know

Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know

Zacks Investment Research

Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?

Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?

PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference

MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York.

PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference

Zacks Investment Research

PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.

PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

24/7 Wall Street

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity

Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference.

PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity

Zacks Investment Research

PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut

PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.

PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut

Pacific Biosciences: It's Only Getting Worse

Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 revenues down, below consensus. Operating and net losses remain sizable, with cash now under $237 million and nearly $645 million in debt outstanding. PACB trades at 2.4x expected 2026 revenues, a steep discount to peers, reflecting weaker financials and growth prospects.

Pacific Biosciences: It's Only Getting Worse

Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript

Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript

Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript

Pacific Biosciences of California Q2 Earnings Call Highlights

Pacific Biosciences of California NASDAQ: PACB reported second-quarter 2026 revenue of $39 million, roughly flat from $39.8 million a year earlier, while announcing an immediate leadership transition and lowering its full-year revenue outlook amid a slower-than-expected rollout of its new multi-use sequencing chemistry and continued funding constraints in academic and government markets.

Pacific Biosciences of California Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™